Adaptive Biotechnologies Corp (ADPT) Stock Price & Analysis

Adaptive Biotechnologies Corp (ADPT) rose 3.95% to USD 17.36 as of June 10, 2026 at 00:59 UTC, according to Nexqual real-time market data.

ADPT last closed at USD 16.7; the session ranged USD 16.54–17.53 on volume of 2,216,573 shares. Market capitalization is $2.78B, with a 52-week range of USD 9.9–20.76 (NMS). Source: Nexqual, June 10, 2026 at 00:59 UTC.

Key Statistics (as of June 10, 2026 at 00:59 UTC)

Technical Analysis (ADPT)

Nexqual's technical model rates ADPT "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:59 UTC.

Analyst Ratings (ADPT)

Wall Street analysts rate ADPT "Strong Buy" based on 7 analysts, with a mean price target of USD 20.14 (range USD 18–22), per Nexqual as of June 10, 2026 at 00:59 UTC.

Earnings (ADPT)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:59 UTC.

Financials & Fundamentals (ADPT)

Source: Nexqual, June 10, 2026 at 00:59 UTC.

Financial Health Score (ADPT)

Nexqual rates Adaptive Biotechnologies Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:59 UTC.

Ownership (ADPT)

Source: Nexqual, June 10, 2026 at 00:59 UTC.

Leadership (ADPT)

Adaptive Biotechnologies Corp is led by Chad M. Robins (age 50), Co-Founder, CEO & Chairman, per Nexqual as of June 10, 2026 at 00:59 UTC.

Major Backers & Investors (ADPT)

Notable institutional backers of Adaptive Biotechnologies Corp include Viking Global, Westfield Capital Management Co LP, Lord, Abbett & Co. LLC, according to Nexqual as of June 10, 2026 at 00:59 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:59 UTC.

From Adaptive Biotechnologies Corp's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Having obtained FDA marketing authorization and expanded coverage to greater than 300 million covered lives for multiple indications of clonoSEQ from Medicare, national private payors and large regional plans, we believe we have developed valuable core capabilities that will facilitate future product development through to regulatory approval and reimbursement. • Our proprietary immune medicine technologies and computational biology capabilities provide a robust product development engine.
• These capabilities enable us to offer an expanding suite of solutions including: immune receptor sequencing, licensing of our proprietary data, TCR-antigen prediction models and our target discovery capabilities.
• As our non-U.S. market access efforts continue to progress, we also anticipate expanding clinical use with our current lab partners in several countries.   9   Reimbursement In January 2019, clonoSEQ received Medicare coverage aligned with the FDA label and National Comprehensive Cancer Network ("NCCN") guidelines for longitudinal monitoring in MM and ALL. clonoSEQ is now incorporated in NCCN guidelines and used by all 33 NCCN cancer centers.
• Over the years since, we have secured additional payor coverage for clonoSEQ aligned with our FDA label with Medicare, national private payors and large regional plans, expanding coverage to over 300 million covered lives for ALL and MM, over 270 million covered lives for CLL and over 90 million covered lives for DLBCL.

Partnerships

• In 2024, we entered into a partnership with Flatiron, a leading provider of electronic health records software and services for community oncology, to integrate clonoSEQ into Flatiron's OncoEMR system, which we launched in July 2025, enabling 113 customer sites.
• In October 2022, we entered into a partnership with Epic to integrate clonoSEQ into Epic's EMR system, which we believe will enable easier test ordering and results access for the clonoSEQ test.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:59 UTC. This page is informational and not investment advice.